Safety profiles with immunotherapy similar among older, younger patients with breast cancer

Older patients undergoing immunotherapy for breast cancer experienced similar rates of immune-related adverse events as younger patients, according to a presenter at San Antonio Breast Cancer Symposium.
Patients aged 65 years or older experienced higher rates of nephritis, whereas those aged younger than 65 years experienced higher rates of transaminitis and higher-grade hypothyroidism.
“Immunotherapy is currently approved for both early- and advanced-stage triple-negative breast cancer. However, the toxicity of immunotherapy and immune related adverse events [among] patients 65 years and

Leave a Comment

Your email address will not be published. Required fields are marked *

Shopping Cart